In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir-Reference-Cited by-同舟云学术

In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir

Published:2019-04 Issue:4 Volume:57 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Han Bin¹,Parhy Bandita¹,Lu Julia¹,Zhou Eric¹,Hsieh David¹,Camus Gregory¹,Martin Ross¹,Svarovskaia Evguenia S.¹,Mo Hongmei¹,Dvory-Sobol Hadas¹

Affiliation:

1. Gilead Sciences, Inc., Foster City, California, USA

Abstract

Voxilaprevir is a direct-acting antiviral agent (DAA) that targets the NS3/4A protease of hepatitis C virus (HCV). High sequence diversity of HCV and inadequate drug exposure during unsuccessful treatment may lead to the accumulation of variants with reduced susceptibility to DAAs, including NS3/4A protease inhibitors such as voxilaprevir.

Funder

Gilead Sciences

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01844-18

Reference55 articles.

1. Viral hepatitis and the Global Burden of Disease: a need to regroup

2. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence

3. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study